ASH 2019 – CLL

ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

The results of this phase 3 study demonstrate a progression-free survival advantage for patients treated with acalabrutinib given alone or in combination with obinutuzumab versus those treated with obinutuzumab plus chlorambucil. Read More ›

Acalabrutinib-Based Combination Treatments for CLL

ASH 2019 – CLL

Results from ELEVATE-TN, a phase 3 study comparing the efficacy and safety of acalabrutinib given as a single agent; acalabrutinib combined with obinutuzumab; and obinutuzumab combined with chlorambucil in patients with untreated chronic lymphocytic leukemia (CLL). Read More ›

Combination Treatment for Follicular Lymphoma

ASH 2019 – CLL

Researchers tested the Pola-G-Len (polatuzumab vedotin, obinutuzumab, and lenalidomide) regimen to determine if it enhanced antitumor response in patients with relapsed or refractory follicular lymphoma. Read More ›

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study

ASH 2019 – Wrap-up, ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features. Read More ›

Third Interim Analysis from the Phase 2 Vision HO141 Trial of Venetoclax + Ibrutinib for Patients with R/R CLL: 15-Month Safety, Response, and MRD Evaluation

ASH 2019 – CLL

ASH 2019 – CLL

Page 3 of 4